Flat-Rate Subscription to La Merie Publishing Reports

Publisher: La Merie Publishing
Format: PDF
Type: Reports
Version: E-Mail Delivery
Product Code: LMDB0003
Release Date: May of 2013

4,000.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Flat-Rate Subscription to La Merie Publishing Reports

Subscription to this product provides access during one year to

  • all existing reports on stock and listed online in the store; and
  • all new reports produced by La Merie Publishing during the term of the subscription.

Among La Merie Publishing reports are Competitor Analysis reports as well as Full Reports. La Merie Publishing reports are continuously updated and new ones released. Reports can be searched for and identified in La Merie Publishing’s online store. After purchase of the product, existing reports will be made available to the customer by e-mail delivery of the pdf reports and/or online access to the archive. New reports will automatically be sent upon release of the report.

Features of the Flat-Rate Access to La Merie Publishing Reports:

  • Dynamic content (more than 50 updates and new releases per year)
  • Convenient e-mail delivery of pdf reports upon subscription and new release
  • Broad coverage of Biosimilars, Antibodies, Proteins and Vaccines  
  • Great savings over individual purchases

Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced. Each project described in the Competitor Analysis reports is specified for its Target or Mechanism of Action, Product Category, Indication,  R&D Phase and Comment with a hyperlink leading to the source of information.

Full Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.

Examples of  Full Reports as of April 2014

  • Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
  • The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
  • Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares
  • Antibody Technologies and Attrition Rates – an industry analysis 2013

Examples of Biosimilar & Biosuperior Protein Reports

  • Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
  • Erythropoiesis Stimulating Agents (ESA)
  • Coagulation Factors
  • G-CSF and GM-CSF
  • Enzyme Replacement Therapies
  • FSH, LH & hCG: Assisted Reproductive Technologies (ART)
  • Interferon
  • Thrombopoiesis Stimulating Agents
  • Insulin
  • Human Growth Hormone
  • Thrombolytic Agents
  • PTH Receptor Agonists, Teriparatide Biosimilars & Biosuperiors

Examples of Biosimilar & Biosuperior Antibody Reports

  • Biosimilar and Biosuperior Therapeutic Antibodies
  • CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors    
  • Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors  
  • VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors         
  • EGF-R Antibodies –Biosimilars and Biosuperiors  
  • TNF Antibodies –Biosimilars and Biosuperiors

Examples of Vaccine Reports

  • Herpes Virus Vaccines and Therapeutics
  • Pneumococcal and Streptococcal Vaccines
  • Tuberculosis Vaccines and Therapeutics
  • Malaria Vaccines & Therapeutics
  • CMV Vaccines & Therapeutics
  • Dengue Virus Vaccines & Therapeutics
  • RSV Vaccines & Therapeutics
  • Pseudomonas Aeruginosa Vaccines & Therapeutics
  • Staphylococcus aureus Vaccines & Therapeutics
  • Cancer Vaccines
  • HIV Vaccines
  • Hepatitis Vaccines
  • Influenza Vaccines
  • HPV Vaccines
  • Anthrax Vaccines & Therapeutics
  • Smallpox Vaccines & Therapeutics
  • Clostridium difficile Vaccines & Therapeutics

Examples  of Other Popular Reports

  • Toll-Like Receptor (TLR) Agonists & Antagonists
  • Cardiovascular Peptides


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up